Polaris Taiwan Subsidiary TDW To Begin Phase III Trials Of Liver Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Phase III clinical trials are slated to start next year on anti-cancer drug ADI-PEG 20 by U.S.-based Polaris Group's Taiwan subsidiary TDW Pharmaceuticals following successful Phase II trials that included recovery by a cancer patient deemed to have six months to live several years ago